Bases racionales de prescripción para médicos neurólogos

Orellana, Lucas; Alemán, Alberto; Barboza, Andrés; Bernater, Ricardo; Demey, Ignacio; Deri, Norma; Fumagalli, Ana Isabel; Kriebaum, Martín; Martinez, Alejandra; Martı́nez, O. E.; Papayannis, Cristina; Marcilla, Marcela Parada; Rojas, Galeno; Romano, Lucas Martín; Romano, Marina; Saidón, P.; Steinberg, Judith

doi:10.1016/j.neuarg.2016.04.002

Cited by 1 publication

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the utilization of NRD for the treatment of CI increases polypharmacy in this vulnerable population, with the evidence‐based negative clinical consequences. Moreover, NRD prescriptions also compromise public health in relation to the direct and indirect costs that they represent …”

Section: Introductionmentioning

confidence: 99%

“…Moreover, NRD prescriptions also compromise public health in relation to the direct and indirect costs that they represent. [15][16][17][18] Comparative studies on the prescription of pharmacological treatment for CI are scarce in Latin America due to the lack of official data from public health systems. 19 It is highly relevant to obtain good quality local data, allowing health authorities to perform appropriate regional health policies.…”

mentioning

confidence: 99%

See 1 more Smart Citation

What is happening with not recommended drugs for dementia in Argentina? Prescription patterns and direct costs analysis

Bustín

Rojas

O'Neill

et al. 2019

Int J Geriat Psychiatry

Self Cite

View full text Add to dashboard Cite

Objectives: The only recommended pharmacological treatments for specific dementias are donepezil, galantamine, rivastigmine, and memantine (recommended drugs, RD). However, other drugs without recommendations (not recommended drugs, NRD) are often used to treat patients with cognitive impairment (CI) in Argentina. The INSSJyP is the largest health insurance in Argentina. The objective of this study is to analyze the prescription pattern, cost, and implications of NRD used for the treatment of CI in the INSSJyP. Materials: This is a retrospective, population-based study of the INSSJyP outpatients' prescriptions database for drugs usually prescribed for CI during 2015. These data were compared with the same database in 2009. The number of "prescriptions" always refers to dispensed packages. Results: A total of 3 255 438 packages of drugs usually indicated for CI were prescribed during 2015: 1 912 476 packages of RD (59%) and 1 342 962 packages of NRD (41%).Comparing the results with those obtained in 2009, there is a 148% gross increase in the prescription of both RD and NRD for CI, although the rates/1000 affiliates/year show a lesser rise for NRD (70.1%) compared to RD (103.9 %).The expenditure on CI drugs prescribed during 2015 was 77 million USD. NRD cost represented approximately 20 million USD. Conclusion: Inappropriate drug use increases health costs in developing countries.We found a high number of patients with a probable diagnosis of CI treated with NRD. It is extremely relevant that all the healthcare professionals can update their knowledge and modify behavioral insights about appropriate prescription for specific dementias.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%